Enovis

ENOV

----

Current ValuationThe current P/E ratio is -1.04, within the reasonable range, cheaper than 24.81% of the time in the past 1 years, and the industry ranks 87/174, the industry Median -0.78.

-1.04xP/E

Stock price$19.91Earnings per share$-19.10

Historical Valuation

P/E ratioTypical rangeMedian

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.

013263952

The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.

0x30x60x90x120x150x

P/E ratio
Name/Symbol
GKOSUSGlaukos	-82.54x	90.98%	$14.01B
BAXUSBaxter	-16.45x	157.75%	$11.89B
TFXUSTeleflex	-5.74x	118.39%	$5.92B
IRTCUSIRhythm	-291.58x	71.47%	$4.07B
PLSEUSPulse Biosciences	-46.54x	26.85%	$3.73B
AXGNUSAxogen	-90.74x	12.42%	$2.90B
ASSTUSStrive	-2.82x	57.99%	$2.75B
KMTSUSKestra Medical Tech	-11.61x	0.79%	$1.74B
BFLYUSButterfly Network	-31.69x	38.71%	$1.70B
NVCRUSNovocure	-12.58x	1.23%	$1.53B
TNDMUSTandem Diabetes	-21.00x	77.60%	$1.33B
DRTSUSAlpha Tau Medical	-13.03x	--	$1.21B
ENOVUSEnovis	-1.04x	100.97%	$1.15B
AORTUSArtivion	-345.01x	266.67%	$1.10B
PRCTUSPROCEPT BioRobotics	-10.02x	3.47%	$1.10B
ATECUSAlphatec	-12.51x	51.04%	$1.09B
CBLLUSCeribell	-15.46x	35.15%	$1.02B
SIBNUSSI-BONE	-65.03x	8.85%	$951.50M
QDELUSQuidelOrtho	-0.87x	75.33%	$908.62M
BBNXUSBeta Bionics	-10.61x	13.37%	$881.75M

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.